Lenomorelin
Also known as: Acylated ghrelin (synthetic), Ghrelin (human), TZP-101, Ulimorelin (related compound)
Source Lenomorelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Lenomorelin (synthetic acylated ghrelin) is an investigational peptide being studied primarily for gastroparesis, cachexia, anorexia associated with chronic illness, and postoperative gastrointestinal dysmotility. It mimics endogenous acylated ghrelin to stimulate GH release and enhance gastric emptying.
Mechanism of Action
Lenomorelin is a synthetic form of acylated ghrelin that binds to and activates the growth hormone secretagogue receptor 1a (GHSR-1a), stimulating growth hormone secretion from the pituitary, promoting appetite, and modulating gastrointestinal motility.
Routes of Administration
Goals & Uses
- Postoperative ileus managementGastrointestinal MotilityModerate
- Improvement of gastroparesis symptomsGastrointestinal MotilityModerate
- Stimulation of growth hormone secretionEndocrineHigh
- Treatment of cancer cachexia / anorexiaNutritional/metabolicModerate
- Short bowel syndrome nutritional supportNutritional/metabolicLow
Contraindications
- Active malignancy with hormone-sensitive tumorsOncologyHigh
- Uncontrolled Diabetes MellitusMetabolic / EndocrineModerate
- Acromegaly or active pituitary adenomaEndocrineHigh
- Known hypersensitivity to ghrelin or its analoguesAllergic/immunologicHigh
Adverse Effects
- HyperglycemiaMetabolicCommonAbnormally high blood glucose
- Injection site reactionsLocalCommon
- Increased appetite/weight gainMetabolicCommon
- FlushingVascularUncommonWarmth and redness of the skin
- Cortisol and prolactin elevationEndocrineUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
Drug Interactions
- Insulin / antidiabetic agentsModerate
- CorticosteroidsLow
- Growth hormone / IGF-1 therapiesModerate
Population Constraints
- Pediatric patientsAgeRelative
- Elderly patientsAgeRelative
- Pregnant womenReproductiveRelative
- Patients with renal or hepatic impairmentOrgan FunctionRelative
Regulatory Status
- European UnionInvestigationalNo EMA marketing authorization; studied in European clinical trials.
- United StatesInvestigationalHas been studied in FDA-registered clinical trials (e.g., gastroparesis, cachexia) but not approved.
- United KingdomInvestigationalNo MHRA approval; remains a research compound.
Not approved by FDA, EMA, or other major regulatory agencies. Has been studied in clinical trials for gastroparesis and cancer cachexia. Developed under the INN 'lenomorelin'; previously investigated by Æterna Zentaris and other sponsors.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Lenomorelin?
Lenomorelin (synthetic acylated ghrelin) is an investigational peptide being studied primarily for gastroparesis, cachexia, anorexia associated with chronic illness, and postoperative gastrointestinal dysmotility. It mimics endogenous acylated ghrelin to stimulate GH release and enhance gastric emptying.
What is Lenomorelin used for?
Lenomorelin is educationally associated with: Postoperative ileus management, Improvement of gastroparesis symptoms, Stimulation of growth hormone secretion, Treatment of cancer cachexia / anorexia, Short bowel syndrome nutritional support. Educational only — not medical advice.
How is Lenomorelin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Lenomorelin?
Reported adverse effects include: Hyperglycemia, Injection site reactions, Increased appetite/weight gain, Flushing, Cortisol and prolactin elevation, Nausea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Lenomorelin?
Recorded contraindications: Active malignancy with hormone-sensitive tumors, Uncontrolled Diabetes Mellitus, Acromegaly or active pituitary adenoma, Known hypersensitivity to ghrelin or its analogues. Consult a qualified clinician before use.